Product Introduction

Pazopanib

Pazopanib is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, PDGFR, FGFR, c-Kit and c-Fms with **IC50** of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.

Technical Data:

Molecular Weight (MW):	437.52	
Formula:	$C_{21}H_{23}N_7O_2S$	
Solubility (25°C) * <1 mg/ml means slightly soluble or insoluble:	DMSO 88 mg/mL	
	Water <1 mg/mL	
	Ethanol <1 mg/mL	
Purity:	>98%	
Storage:	3 years -20℃Powder	
	6 months-80℃in DMSO	
CAS No.:	444731-52-6	

Biological Activity

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 μg/mL of Pazopanib and is completely abolished at 5 μg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m

g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

References

[1] Harris PA, et al. J Med Chem. 2008, 51(15), 4632-4640.

[2] Hosaka S, et al. J Orthop Res. 2012.

[3] Kernt M, et al. Retina. 2012.

Note： Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer’s risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.